Ozmosi | Oblimersen Drug Profile

Product Description

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: European Medicines Agency

Approved Indications: None

Known Adverse Events: None

Company: Genta
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Lymphoid Leukemia|Melanoma|Acute Myeloid Leukemia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00736450	0462-07-FB	P1	Terminated	Diffuse Large B-Cell Lymphoma\|Lymphoma, Non-Hodgkin	2012-10-09	2024-11-27	Primary Endpoints
NCT00060112	NCI-2012-02531	P1	Terminated	Lymphocytic Chronic B-Cell Leukemia\|Adult T-Cell Leukemia-Lymphoma\|Mantle-Cell Lymphoma\|Large-Cell Immunoblastic Lymphoma\|B-Cell Marginal Zone Lymphoma\|Plasmablastic Lymphoma\|Lymphoma, Non-Hodgkin\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|T-Cell Cutaneous Lymphoma\|Diffuse Large B-Cell Lymphoma\|Burkitt Lymphoma\|Follicular Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Lymphoid Leukemia\|Leukemia, Plasma Cell\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	2009-12-01	2019-03-21	Treatments
NCT00054548	NCI-2013-00010	P1	Completed	Oncology Solid Tumor Unspecified	2008-05-01	2020-10-26	Primary Endpoints\|Treatments
NCT00636545	GPK109	P1	Completed	Oncology Solid Tumor Unspecified	2008-03-01	2019-03-18
NCT00543075	GPK104	P1	Completed	Kidney Diseases	2007-11-01	2019-03-21	Treatments
NCT00039481	NCI-2012-01872	P1	Completed	Oncology Solid Tumor Unspecified	2005-10-01	2024-11-27
NCT01200342	NCT01200342	P2	Terminated	Melanoma	2013-09-01	2019-03-19
NCT00064259	NCI-2012-03134	P2	Terminated	Esophageal Cancer\|Adenocarcinoma\|Gastrointestinal Cancer\|Squamous Cell Carcinoma	2010-02-01	2020-10-26	Primary Endpoints\|Treatments
NCT00054639	NCI-2011-00617	P2	Completed	Adult T-Cell Leukemia-Lymphoma\|Large-Cell Immunoblastic Lymphoma\|Extranodal NK-T-Cell Lymphoma\|Follicular Lymphoma\|Mantle-Cell Lymphoma\|Waldenstrom Macroglobulinemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin\|B-Cell Marginal Zone Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Intraocular Lymphoma\|Leukemia, Plasma Cell\|Chronic Lymphoid Leukemia\|Burkitt Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Diffuse Large B-Cell Lymphoma\|Lymphomatoid Granulomatosis\|T-Cell Cutaneous Lymphoma\|Plasmablastic Lymphoma	2010-01-01	2019-03-21	Treatments
NCT00047229	PMH-PHL-011	P2	Completed	Liver Cancer\|Hepatocellular Carcinoma	2009-01-01	2024-11-27
NCT00078234	GL217	P2	Completed	Lymphocytic Chronic B-Cell Leukemia\|Chronic Lymphoid Leukemia	2008-09-01	2019-03-21	Treatments
NCT00063934	NCI-2012-02885	P2	Terminated	Male Breast Cancer	2008-02-01	2024-11-27	Primary Endpoints
NCT00301795	NCI-2012-03080	P2	Terminated	Lymphoma, Non-Hodgkin\|Follicular Lymphoma	2007-11-01	2020-10-26	Primary Endpoints\|Treatments
NCT00080847	NCI-2012-03031	P2	Terminated	Lymphoma, Non-Hodgkin\|Diffuse Large B-Cell Lymphoma	2007-06-01	2024-11-27
NCT00062244	NCI-2012-01437	P2	Completed	Waldenstrom Macroglobulinemia	2007-06-01	2020-10-26	Primary Endpoints
NCT00079131	NCI-2012-01446	P2	Completed	Neuroendocrine Carcinoma\|Carcinoma, Merkel Cell	2007-01-01	2019-03-21	Treatments
2004-002094-23	2004-002094-23	P2	Completed	Prostate Cancer	2006-09-29	2022-03-12	Treatments
NCT00086944	NCI-2012-02600	P2	Completed	Lymphoma, Non-Hodgkin\|Mantle-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma	2006-07-01	2024-11-27	Primary Endpoints\|Treatments
NCT00091078	NCI-2012-02883	P2	Terminated	Gastrointestinal Stromal Tumors	2006-07-01	2019-03-21	Treatments
NCT00085228	EORTC-30021	P2	Completed	Prostate Cancer\|Adenocarcinoma	2006-01-01	2019-03-21	Treatments
NCT00049192	NCI-2012-02790	P2	Completed	Chronic Myeloid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2005-11-01	2020-10-26	Primary Endpoints\|Treatments
NCT00518895	AGENDA	P3	Completed	Melanoma	2011-05-01	2019-03-21
2007-003340-30	2007-003340-30	P3	Completed	Melanoma	2011-04-28	2022-03-12	Treatments
NCT00085124	NCI-2012-02805	P3	Completed	Acute Myeloid Leukemia	2007-06-01	2024-11-27	Primary Endpoints\|Treatments
NCT00543205	GPK103	P3	Terminated	Melanoma	2007-05-01	2019-03-21	Treatments

Recent News Events

Date	Type	Title
12/20/2023	PubMed	Bcl-2 expression in cell lines breast cancer and death program.
06/13/2023	PubMed	Metal-Organic Frameworks Facilitate Nucleic Acids for Multimode Synergistic Therapy of Breast Cancer.
02/01/2023	PubMed	[Effect of erastin and G3139 on rat liver mitochondria in chronic alcoholic intoxication].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Oblimersen

Alternative Names: oblimersen, g3139 Clinical Status: Inactive Latest Update: 2024-05-30 Latest Update Note: Clinical Trial Update